Growth hormone does a lot of things. It promotes growth (obviously), affects glucose metabolism, drives lipolysis (fat breakdown), and influences tissue repair. But what if you could isolate just the fat-burning part and leave the rest behind?
That’s exactly what a team of Australian researchers set out to do. They clipped out a small piece of the GH molecule — amino acids 177-191, plus a tyrosine at the front — and tested whether this fragment retained GH’s metabolic effects without its growth-promoting or diabetogenic properties. The result was AOD9604, and the published research suggests they were onto something.
This compound is supplied exclusively for in vitro and preclinical research. It is not intended for human consumption, therapeutic application, or diagnostic use.
The Logic: Growth Hormone Is Modular
The story starts with an observation that reshaped how researchers think about growth hormone: GH’s effects aren’t all coming from the same part of the molecule. Different regions appear to drive different functions. The C-terminal region (the tail end of the protein) was identified as particularly relevant to lipid metabolism — the fat-burning machinery.
Metabolic Pharmaceuticals in Melbourne took this insight and ran with it. They isolated the 177-191 fragment, added an N-terminal tyrosine for stability and detection purposes, and began systematic testing. The question: does this fragment retain the metabolic effects of full GH without the baggage?
What the Published Research Shows
Fat Metabolism Without Growth
Ng et al. published the foundational work showing that AOD9604 stimulated lipolysis (fat breakdown) in adipose tissue models while not promoting IGF-1 elevation or longitudinal bone growth. This is the key finding: the fat-metabolizing properties of GH are separable from its growth-promoting properties.
In obese rodent models (ob/ob mice and Zucker fatty rats), AOD9604 treatment reduced body fat accumulation without affecting lean mass or food intake. The weight change was specific to adipose tissue — exactly what you’d want if you’re trying to study metabolic effects of GH fragments in isolation.
No Diabetogenic Effect
Full-length growth hormone can worsen insulin sensitivity — the “diabetogenic” effect that limits its use in metabolic research. AOD9604 was specifically studied for this, and the published data shows it didn’t impair glucose tolerance or insulin sensitivity in animal models. The glucose-metabolism baggage was left behind with the rest of the GH molecule.
The Mechanism: β3-Adrenergic Receptors
Research into how AOD9604 produces its lipolytic effects has pointed to the β3-adrenergic receptor pathway. This is the same receptor system that mediates cold-induced thermogenesis and brown adipose tissue activation — the body’s natural fat-burning infrastructure. AOD9604 appears to enhance lipolysis through this pathway rather than through the GH receptor, which explains why it doesn’t trigger IGF-1 elevation or the other endocrine effects of full GH.
Cartilage and Joint Research
An interesting secondary research area: AOD9604 has been investigated for effects on cartilage metabolism. Studies reported chondroprotective properties — the ability to protect cartilage cells and potentially support cartilage repair processes. This research led to regulatory approval in Australia for AOD9604 as a food supplement, though this is separate from its primary metabolic research applications.
The Clinical Story (And Why It Stalled)
AOD9604 advanced to Phase II clinical trials for obesity in humans. The trials showed a favorable safety profile but didn’t meet the primary endpoints for statistically significant weight loss at the doses tested. Metabolic Pharmaceuticals eventually discontinued development for this indication.
Does that mean it doesn’t work? Not necessarily. Clinical trial failure often reflects dose selection, study design, or endpoint definition rather than a fundamental lack of activity. The preclinical evidence for metabolic effects remains published and peer-reviewed. What it means is that the translation from rodent models to human clinical endpoints proved more complex than hoped — a common story in pharmaceutical development.
AOD9604 vs Full Growth Hormone
The comparison is the whole point:
- Lipolysis: AOD9604 ✓ | Full GH ✓
- Growth promotion/IGF-1: AOD9604 ✗ | Full GH ✓
- Diabetogenic effect: AOD9604 ✗ | Full GH ✓
- Bone growth: AOD9604 ✗ | Full GH ✓
For researchers studying fat metabolism specifically, this selectivity is the value proposition — isolated metabolic effects without systemic endocrine confounders.
Product Specifications
- Fragment: hGH 177-191 with N-terminal tyrosine
- Molecular Weight: 1,815.08 g/mol
- CAS Number: 221231-10-3
- Physical Form: Sterile lyophilized white powder
- Purity: ≥99% (verified by HPLC)
- Solubility: Freely soluble in bacteriostatic water
Key References
- Ng FM, et al. Metabolic effects of a synthetic lipolytic domain (AOD9604) of human growth hormone. Horm Res. 2000.
- Heffernan M, et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism. Endocrinology. 2001.
- Stier H, et al. Safety and tolerability of the hexadecapeptide AOD9604 in humans. Growth Horm IGF Res. 2013.
Browse AOD9604 5mg with verified COA from Janoshik Analytical. For related metabolic research, see GLP-1S, 5-Amino-1MQ, and our Metabolic Research category.